After promising activity in melanoma was reported, trials in lung cancer demonstrated that the combination of a PD-1 inhibitor and anti CTLA-4 antibody was active, with an ORR of 13%-20%.52 This evidence concerns the gene PDCD1 and lung carcinoma.